Media.Player

Hybrid IgA/IgG Polymeric Antibodies

Technology Benefits

The IgA/IgG hybrid has the pH stability of an IgA molecule The IgA/IgG hybrid has complement fixing activity greater than monomeric IgG molecules. Can produce the IgA/IgG hybrib monoclonal antibodies in large quantities using standard antibody production techniques.

Technology Application

Recombinant antibody therapies

Detailed Technology Description

UCLA researchers have engineered IgA/IgG hybrid antibodies that combine characteristics of both IgA and IgG into a single immunoglobulin molecule. The IgG constant region was enhanced with the addition of IgA constant regions. This addition resulted in a molecule that has the pH stability of IgA and greater complement fixing activity than IgG due to its polymeric structure. By utilizing this technology, any variable region can be paired with the IgA/IgG hybrid to yield an immunoglobulin molecule with unique effector functions.

Supplementary Information

Patent Number: US6284536B1
Application Number: US1999295283A
Inventor: Morrison, Sherie L. | Chintalacharuvu, Koteswara R. | Yoo, Esther Mikyung | Trinh, Kham M. | Coloma, M. Josefina
Priority Date: 20 Apr 1998
Priority Number: US6284536B1
Application Date: 20 Apr 1999
Publication Date: 4 Sep 2001
IPC Current: C07K001600 | C07K001646 | C12P002108 | A61K003800
US Class: 435328 | 4241331 | 4241601 | 4241611 | 435005 | 4350071 | 4350697 | 4350701 | 4353201 | 4353391 | 5303873 | 5360235 | 53602343
Assignee Applicant: The Regents of the University of California
Title: Modified immunoglobulin molecules and methods for use thereof | Modified immunoglobin molecules and methods for use thereof
Usefulness: Modified immunoglobulin molecules and methods for use thereof | Modified immunoglobin molecules and methods for use thereof
Summary: (I) may be used to treat or prevent a systemic, local or mucosal infection in a mammal, bird, reptile or fish. The types of infection that may be treated include bacterial, mycoplasmal, mycobacterial, yeast or parasitic infections, especially HIV, hepatitis, respiratory syncytial virus, influenza or cold viral infections (all claimed).
Novelty: New modified immunoglobulin molecules, useful for treatment and prevention of infectious diseases

Industry

Disease Diagnostic/Treatment

Sub Category

HIV

Application No.

6284536

Others

Background

IgA is a polymeric effector molecule of the immune system that mainly acts at mucosal surfaces and is highly resistant to extreme pH conditions, whereas IgG is monomeric and acts in the blood at a narrower pH range. IgG is known for its potent complement activation and, in contrast, IgA is unable to fix complement. Combining the characteristics of IgA and IgG into a single immunoglobulin molecule may produce more effective therapeutic agents.

Additional Technologies by these Inventors

• Vectors for the Recombinant Expression of Human Immunoglobulins
• Improved Rh (D) Human Blood Typing Reagent
• Antibody Fusion Proteins for Treating Cancer
• Production of Secretory IgA with Increased Stability
• Vectors for Antibody Expression
• Anti-Cspg4 Fusions with Type I Interferon for the Treatment of Malignancy

Tech ID/UC Case

20084/1998-610-0

Related Cases

1998-610-0

*Abstract

None

*IP Issue Date

Sep 4, 2001

*Principal Investigator

Name: Koteswara Chintalacharuvu

Department:

Name: Maria Coloma

Department:

Name: Sherie Morrison

Department:

Name: Kham (Ryan) Trinh

Department:

Name: Esther Yoo

Department:

Country/Region

USA